Status:
COMPLETED
Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma
Lead Sponsor:
Allergan
Conditions:
Glaucoma, Open-Angle
Ocular Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This is an exploratory study that will evaluate the safety and pharmacodynamics of up to 3 doses of AGN-207281 based on an ongoing review of data during the study period compared with timolol ophthalm...
Eligibility Criteria
Inclusion
- Ocular hypertension or primary open-angle glaucoma in each eye
- Requires IOP-lowering therapy in both eyes
- Visual acuity score of 20/100 or better in each eye
Exclusion
- Experienced significant weight change (over 10 pounds) within 60 days
- History of alcohol or drug addiction
- History of migraines or frequent headaches
- Anticipated wearing of contact lenses during the study
- Required chronic use of ocular medications during study
- Eye surgery within 6 months
- Use of systemic beta blockers (eg, atenolol, propranolol) within 2 months
- Use of oral, intramuscular, intravenous corticosteroids within 21 days
- Use of ophthalmic corticosteroids within 2 months
Key Trial Info
Start Date :
October 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT01215786
Start Date
October 1 2010
End Date
December 1 2010
Last Update
August 17 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Newport Beach, California, United States